<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t1-idr-8-269" position="float">
 <label>Table 1</label>
 <caption>
  <p>Properties of the terminase inhibitor letermovir (AIC246)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1"/>
    <th valign="top" align="left" rowspan="1" colspan="1">Description</th>
    <th valign="top" align="left" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Molecule type</td>
    <td valign="top" align="left" rowspan="1" colspan="1">3,4-dihydro-quinazoline-4-yl-acetic acid derivative</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Lischka et al
     <xref rid="b38-idr-8-269" ref-type="bibr">38</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Mechanism of action</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibits terminase complex subunit pUL56</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Goldner et al
     <xref rid="b44-idr-8-269" ref-type="bibr">44</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Known resistance mutations</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <italic>UL56</italic>: L241P and R369S
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Goldner et al
     <xref rid="b46-idr-8-269" ref-type="bibr">46</xref>
     <break/>Goldner et al
     <xref rid="b45-idr-8-269" ref-type="bibr">45</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Cross-resistance with other antivirals</td>
    <td valign="top" align="left" rowspan="1" colspan="1">None identified</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Goldner et al
     <xref rid="b44-idr-8-269" ref-type="bibr">44</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Letermovir remains active against CMV strains resistant to the other anti-CMV drugs
     <break/>GCV remains active against letermovir-resistant CMV strains
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Goldner et al
     <xref rid="b44-idr-8-269" ref-type="bibr">44</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Spectrum of activity</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Letermovir is only active against human CMV. No activity has been seen against non-human CMV, other herpesviruses, or any other virus</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Marschall et al
     <xref rid="b43-idr-8-269" ref-type="bibr">43</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical studies</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase IIa: 27 solid organ transplant recipients with active CMV viral replication
     <break/>Findings: doses of 40 mg twice per day or 80 mg daily for 14 days reduced CMV DNA compared with baseline levels
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Stoelben et al
     <xref rid="b40-idr-8-269" ref-type="bibr">40</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase II: 131 CMV seropositive HSCT recipients
     <break/>Findings: letermovir groups had lower rates of prophylaxis failure than placebo (60, 120, or 240 mg of letermovir). Virologic failure was significantly lower in 240 mg group compared with placebo (6% versus 36%)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Chemaly et al
     <xref rid="b42-idr-8-269" ref-type="bibr">42</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Potential use in severe CMV disease</td>
    <td valign="top" align="left" rowspan="1" colspan="1">In vitro studies support its potential use in high viral load infections.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Lischka et al
     <xref rid="b38-idr-8-269" ref-type="bibr">38</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">The successful treatment of a multidrug-resistant CMV infection in a lung transplant recipient was reported</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Kaul et al
     <xref rid="b41-idr-8-269" ref-type="bibr">41</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Side effects</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Uncommon; letermovir is generally well tolerated</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Kropeit
     <xref rid="b47-idr-8-269" ref-type="bibr">47</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Gastroenteritis, nasopharyngitis, dyspnea, and elevation in serum creatinine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Stoelben et al
     <xref rid="b40-idr-8-269" ref-type="bibr">40</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">No reported neutropenia or other major laboratory alterations</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Chemaly et al
     <xref rid="b42-idr-8-269" ref-type="bibr">42</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Pharmacokinetic parameters</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Median T
     <sub>max</sub> was 1.5 hours
     <break/>Mean terminal t
     <sub>1/2</sub> of 10 hours
     <break/>With food, median T
     <sub>max</sub> 4 hours, and C
     <sub>max</sub> was reduced by 24%, but the area under the curve was unchanged
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Kropeit
     <xref rid="b47-idr-8-269" ref-type="bibr">47</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Dosing</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Once-daily dose of 120 mg or 240 mg would achieve desirable levels without compromising its tolerability profile</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Kropeit
     <xref rid="b47-idr-8-269" ref-type="bibr">47</xref>
     <break/>Chemaly et al
     <xref rid="b42-idr-8-269" ref-type="bibr">42</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug interactions</td>
    <td valign="top" align="left" rowspan="1" colspan="1">No significant drug interactions (only moderate increases in the levels of midazolam, tacrolimus, and cyclosporine were observed among healthy volunteers)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">McCormick
     <xref rid="b48-idr-8-269" ref-type="bibr">48</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Potential future applications for letermovir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CMV prophylaxis of solid organ and stem cell transplant recipients
     <break/>First-line or second-line in the treatment of CMV disease
     <break/>Treatment of severe, multidrug-resistant CMV disease
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tfn1-idr-8-269">
   <p>
    <bold>Abbreviations:</bold> CMV, cytomegalovirus; GCV, ganciclovir; HSCT, hematopoietic stem cell transplant; T
    <sub>max</sub>, time to maximum serum concentration; C
    <sub>max</sub>, peak serum concentration; t
    <sub>1/2</sub>, terminal half-life.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
